Comparison
Cagrilintide vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Cosmetic
CAS no.
1415456-99-3
868844-74-0
Molecular weight
4253.7 g/mol
1075.16 g/mol
Half-life
168 h
no data
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
3
of which in humans
3
1
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1